Cooperation on Projects | Leto Laboratories and Hanson Pharmaceutical Entered into Cooperation in Developing a New Drug for Metabolic Diseases
In September 2021, the Hanson Pharmaceutical Group Co., Ltd. (HKEX: 3692) ("Hanson Pharmaceutical") and Leto Laboratories Co., Ltd. ("Leto Laboratories") signed a co-development agreement, in which the parties agreed to carry out a cooperation on metabolic disease projects to facilitate the development and production of a new drug molecule.
Published: September 13, 2021
Leto Laboratories Raises over $15 Million in Series B+ Financing Round for Protein Engineering
Leto Laboratories Co., Ltd. ("Leto Labs") announced the closing of a Series B+ financing of over $15.64 Million (RMB 100 million) from China Capital Management Co., Ltd. The company intends to use the proceeds to continue the development of its polypeptides and anticancer cytokines pipeline.
Published: August 4, 2021
ChosenMed and Leto Laboratories Entered into a Strategic Cooperation on Predictive and Prognostic Molecular Marker Research for Solid Tumor Immunotherapy
On 19 January 2021, ChosenMed Technology (Beijing) Co., Ltd. (“ChosenMed”) and Leto Laboratories Co., Ltd. (“Leto Laboratories”) signed a strategic cooperation agreement in Beijing, to research in tandem on predictive and prognostic molecular markers for immunotherapy in solid tumors and advance the registration of companion diagnostic devices.
Published: January 19, 2021
Leto Laboratories, a company on new drug (protein-based drug) development, completed Series B financing of over $15 million for clinical development of cytokine drugs
Leto Laboratories Co., Ltd. (“Leto Laboratories”) today announced it has completed a $15+ million Series B funding round, invested by Yijing Capital, Qiaojing Capital, and Beijing Changping Science Park Development. Instant Capital was the exclusive financial advisor.
Published: October 16, 2020
$150 Million- TopAlliance Obtains a Global License for an IL-2 Drug from Leto Laboratories
TopAlliance announced a recent agreement with Leto Laboratories, the “Technology License Contract for an IL-2 Drug with Unique Intramolecular Disulfide Bonds”, on August 28th. TopAlliance is exclusively licensed for the preclinical development, clinical research, and commercialization of this IL-2 drug (Code Name: LTC002) and for the use of related patented technology worldwide. The prepayment, milestone payments, and technical service fees of this transaction amount to over $150 million (959 million RMB).
Published: August 29, 2021
Leto Laboratories Grants Exclusive License to TopAlliance (01877) for an Interleukin-2 (IL-2) Drug
(ZhiTong Financial Information Technology, News on App)- TopAlliance (01877) announced the signing of an agreement with Leto Laboratories Co., Ltd. (Leto Laboratories), the“Technology License Contract for an IL-2 Drug with Unique Intramolecular Disulfide Bonds”. TopAlliance is exclusively licensed for the preclinical development, clinical research, and commercialization of this IL-2 drug (Code Name: LTC002) and for the use of related patented technology worldwide.
Published: August 28，2020
State-of-the-Art Technology Facilitates Protein Manufacturing
Today let me introduce a successful case related to this topic- how Leto Laboratories Co., Ltd. develops and manufactures ACE2, a recombinant protein, with BioAccord system of Waters. This system has been used for virus research, development and quality control of vaccines, diagnostic reagents and therapeutic medications in many world-renowned research institutions and firms.
Published: May 15 ，2020
Biotech company Leto Laboratories raises tens of millions of RMB in Series A funding round
Biotech company Leto Laboratories raises tens of millions of RMB in Series A funding round, led by Med-Fine Capital and co-invested by Hygeia Capital, Qirong Venture Capital, and its existing investor SHERPA Healthcare Partners.
Published: March 19, 2019
No more data……